Pharmaceutical Bio Association and Regenerative Medical Technology Development Project Group Sign Exchange Cooperation MOU

Joinho Jo, Director of the Pan-Government Regenerative Medicine Technology Development Project Group (left), and Heemok Won, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, are signing a business agreement and taking a commemorative photo at the Korea Pharmaceutical Association Building in Seocho-gu, Seoul on the 21st.

[Asia Economy Reporter Chunhee Lee] The Korea Pharmaceutical and Bio-Pharma Manufacturers Association announced on the 22nd that it signed a memorandum of understanding (MOU) with the Pan-Government Regenerative Medicine Technology Development Project Group on the 21st at the Pharmaceutical Hall in Seocho-gu, Seoul, to support the advancement of the regenerative medicine field.

Going forward, the two organizations plan to actively cooperate in ▲ exchanging information and establishing industry-academia-research-hospital collaboration networks in the pharmaceutical, bio, and regenerative medicine sectors ▲ improving systems and regulations related to the pharmaceutical and bio industries and regenerative medicine, external promotion, and joint event cooperation ▲ open innovation for the development and commercialization of advanced biopharmaceuticals based on regenerative medicine technologies ▲ and advancing into the global market for pharmaceutical, bio, and regenerative medicine industries.

They also agreed to contribute to the development of the pharmaceutical, bio, and regenerative medicine industries by building information exchange and industry-academia-research-hospital collaboration networks, and to produce results based on mutual cooperation and active exchange.

Won Hee-mok, chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, said, “The establishment of information exchange and industry-academia-research-hospital collaboration networks between the pharmaceutical, bio, and regenerative medicine sectors is expected to be a great driving force for the development and commercialization of advanced biopharmaceuticals.” Jo In-ho, head of the project group, also said, “We hope that this agreement will lead to concrete cooperation plans in the regenerative medicine field, which will be the main pillar of the future bio industry.”

The Pan-Government Regenerative Medicine Technology Development Project Group is the planning and management organization for research and development projects aimed at securing core foundational technologies for regenerative medicine and regenerative medicine therapeutics and treatment technologies through clinical linkage. It was launched in July last year.

This content was produced with the assistance of AI translation services.